Difference between revisions of "Atovaquone (Mepron)"
m |
m (→References) |
||
Line 16: | Line 16: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
− | [[Category: | + | [[Category:Antibacterials]] |
[[Category:PCP prophylaxis]] | [[Category:PCP prophylaxis]] | ||
[[Category:Drugs FDA approved in 1992]] | [[Category:Drugs FDA approved in 1992]] |
Revision as of 02:57, 13 November 2014
General information
Class/mechanism: Antiprotozoal, antimicrobial. Hydroxy-1,4-naphthoquinone, analog of ubiquinone, with antipneumocystis activity. Exact mechanism unclear, but may involve inhibition of the electron transport chain in mitochondria and downstream inhibition of nucleic acid and ATP synthesis.[1][2]
Route: PO (typically as liquid suspension)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
No known antineoplastic properties.